Positive results from the ADEPT Phase II/III study indicate that Dupixent (dupilumab) may be effective in treating ...

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly ...

Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a ...

Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a late ...

Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a ...

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for dupilumab to treat adults with bullous pemphigoid. Bullous pemphigoid ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) recently presented positive results from its Dupixent trial for bullous pemphigoid at the AAD Annual Meeting, demonstrating its ongoing strides in addressing ...

“People with bullous pemphigoid live with unrelenting itch, blisters and painful lesions that can be debilitating and make it difficult to function daily. Moreover, current treatment options can ...